Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.770
+0.050 (2.91%)
Nov 21, 2024, 4:00 PM EST - Market closed
PACB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 173.15 | 200.52 | 128.3 | 130.51 | 78.89 | 90.89 | Upgrade
|
| Revenue Growth (YoY) | 2.14% | 56.29% | -1.69% | 65.43% | -13.20% | 15.60% | Upgrade
|
| Cost of Revenue | 118.91 | 142.32 | 74.83 | 71.35 | 46.33 | 56.32 | Upgrade
|
| Gross Profit | 54.23 | 58.2 | 53.47 | 59.17 | 32.57 | 34.58 | Upgrade
|
| Selling, General & Admin | 164.97 | 169.82 | 160.85 | 124.12 | 72.8 | 75.49 | Upgrade
|
| Research & Development | 146.1 | 187.17 | 193 | 112.9 | 64.15 | 59.63 | Upgrade
|
| Operating Expenses | 338.47 | 365.13 | 354.59 | 237.33 | 136.95 | 135.12 | Upgrade
|
| Operating Income | -284.24 | -306.93 | -301.11 | -178.16 | -104.39 | -100.55 | Upgrade
|
| Interest Expense | -14.23 | -14.34 | -14.69 | -12.53 | -0.27 | -2.61 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.25 | 16.41 | 3.69 | 4.1 | 1.95 | 0.11 | Upgrade
|
| EBT Excluding Unusual Items | -288.21 | -304.86 | -312.12 | -186.59 | -102.7 | -103.05 | Upgrade
|
| Merger & Restructuring Charges | -24.76 | -9.04 | - | -83.13 | 34 | 18 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.42 | 12.84 | 0.24 | -4.01 | 0.11 | 0.91 | Upgrade
|
| Other Unusual Items | -2.2 | -17.09 | -2.38 | -1.14 | 98 | - | Upgrade
|
| Pretax Income | -394.96 | -318.16 | -314.25 | -274.87 | 29.4 | -84.13 | Upgrade
|
| Income Tax Expense | -0.72 | -11.42 | - | -93.65 | - | - | Upgrade
|
| Net Income | -394.24 | -306.74 | -314.25 | -181.22 | 29.4 | -84.13 | Upgrade
|
| Net Income to Common | -394.24 | -306.74 | -314.25 | -181.22 | 29.4 | -84.13 | Upgrade
|
| Shares Outstanding (Basic) | 271 | 254 | 225 | 204 | 165 | 153 | Upgrade
|
| Shares Outstanding (Diluted) | 271 | 254 | 225 | 204 | 175 | 153 | Upgrade
|
| Shares Change (YoY) | 11.16% | 12.95% | 10.00% | 16.67% | 14.71% | 12.90% | Upgrade
|
| EPS (Basic) | -1.46 | -1.21 | -1.40 | -0.89 | 0.18 | -0.55 | Upgrade
|
| EPS (Diluted) | -1.46 | -1.21 | -1.40 | -0.89 | 0.17 | -0.55 | Upgrade
|
| Free Cash Flow | -239.56 | -268.02 | -279.96 | -117.11 | 18.46 | -81.15 | Upgrade
|
| Free Cash Flow Per Share | -0.89 | -1.06 | -1.25 | -0.57 | 0.11 | -0.53 | Upgrade
|
| Gross Margin | 31.32% | 29.02% | 41.68% | 45.33% | 41.28% | 38.04% | Upgrade
|
| Operating Margin | -164.16% | -153.07% | -234.69% | -136.51% | -132.31% | -110.62% | Upgrade
|
| Profit Margin | -227.69% | -152.97% | -244.92% | -138.85% | 37.27% | -92.57% | Upgrade
|
| Free Cash Flow Margin | -138.36% | -133.66% | -218.20% | -89.73% | 23.40% | -89.28% | Upgrade
|
| EBITDA | -242.92 | -287.21 | -290.72 | -170.58 | -97.96 | -93.28 | Upgrade
|
| EBITDA Margin | -140.30% | -143.23% | -226.59% | -130.70% | -124.16% | -102.63% | Upgrade
|
| D&A For EBITDA | 41.32 | 19.72 | 10.39 | 7.58 | 6.43 | 7.27 | Upgrade
|
| EBIT | -284.24 | -306.93 | -301.11 | -178.16 | -104.39 | -100.55 | Upgrade
|
| EBIT Margin | -164.16% | -153.07% | -234.69% | -136.51% | -132.31% | -110.62% | Upgrade
|
| Revenue as Reported | 173.15 | 200.52 | 128.3 | 130.51 | 78.89 | 90.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.